Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Kinase-independent role for CRAF-driving tumour radioresistance via CHK2.

Nature communications - 3 Sept 2015

Advani Sunil J, Camargo Maria Fernanda, Seguin Laetitia, Mielgo Ainhoa, Anand Sudarshan, Hicks Angel M, Aguilera Joseph, Franovic Aleksandra, Weis Sara M, Cheresh David A

Abstract excerpt

Although oncology therapy regimens commonly include radiation and genotoxic drugs, tumour cells typically develop resistance to these interventions. Here we report that treatment of tumours with ionizing radiation or genotoxic drugs drives p21-activated kinase 1 (PAK1)-mediated phosphorylation of CRAF on Serine 338 (pS338) triggering a kinase-independent mechanism of DNA repair and therapeutic resistance. CRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Checkpoint Kinase 2
Share to HCT116 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoprecipitation

Share to Neoplasm Transplantation

Share to p21-Activated Kinases

Share to Proto-Oncogene Proteins c-raf

Share to Radiation, Ionizing

Share to Radiation Tolerance

Source

Open in PubMed Open full text

Identifiers

PMID: 26333361
DOI: 10.1038/ncomms9154
PMCID: PMC4559870

Genes

PAK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Kinase-independent role for CRAF-driving tumour radioresistance via CHK2.PMID 26333361Read ↗

Molecular targets that sensitize cancer to radiation killing: From the bench to the bedsideSemantic proximity Read ↗

Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA DamageSemantic proximity Read ↗

Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA DamageSemantic proximity Read ↗

Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.Semantic proximity Read ↗

Dual Targeting of DNA Damage Response Proteins Implicated in Cancer RadioresistanceSemantic proximity Read ↗

The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase InhibitorsSemantic proximity Read ↗

Ras–MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer CellsSemantic proximity Read ↗

Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapySemantic proximity Read ↗

Chk1 Inhibitors for Novel Cancer TreatmentSemantic proximity Read ↗

Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti‐cancer therapy?Semantic proximity Read ↗

Targeting the ATM Kinase to Enhance the Efficacy of Radiotherapy and Outcomes for Cancer PatientsSemantic proximity Read ↗

MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK ActivationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.